Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (humanized mAb anti-CD115) to be Presented at AACR

information fournie par Boursorama •19/03/2015 à 09:30

Strasbourg, France, March 19, 2015 – Transgene (Euronext: TNG) today announced that new pre-clinical data with two of its immunotherapy programs will be presented at the Annual Meeting of the American Association for Cancer Research (AACR) to be held in Philadelphia, Pennsylvania April 18-22, 2015.

A poster regarding TG4010, Transgene’s immunotherapy that is in late-stage clinical testing for non-small cell lung cancer, will be presented:
Additionally, a poster with data on the Company’s pre-clinical stage anti-cancer monoclonal antibody, TG3003, will be presented:
A third poster reviewing clinical experience with Transgene’s modified vaccinia virus Ankara (MVA) platform will also be presented: